Methods. An isogenic ksl(k2)ABCDE mutant of extraintestinal pathogenic E. coli (ExPEC) strain CFT073 that could not synthesize the K2 capsule was compared with wild-type CFT073, to determine virulence in a murine model of ascending UTI and in vitro killing assays.
Extraintestinal pathogenic Escherichia coli (ExPEC) strains cause the majority of urinary tract infections (UTIs) in humans. Most UTIs develop when microorganisms that colonize the periurethral mucosa ascend through the urethra to the bladder to cause cystitis. The bacteria may progress further via the ureters to the kidneys, producing pyelonephritis, and they may breach the kidney parenchyma to enter the lymphatic system or the bloodstream, resulting in bacteremia. ExPEC strains are responsible for 70%-90% of the 7 million cases of acute cystitis and for the 250,000 cases of pyelonephritis reported annually in the United States [1] . ExPEC strains differ from commensal E. coli because they possess specific virulence factors that allow them to colonize extraintestinal mucosal surfaces, circumvent host defenses, and invade the normally sterile urinary tract. Numerous putative urovirulence factors have been identified for ExPEC strains, including several fimbriae, flagella, toxins, iron uptake systems, extracellular polysaccharides, transcriptional regulators, and certain metabolic factors. However, only a few of these factors, including type 1 fimbriae, TonB, transcriptional regulator RfaH, PhoU, and DegS, have been demonstrated to play a role in acute experimental UTI by use of isogenic mutants and complemented strains [2] [3] [4] [5] [6] .
Extracellular polysaccharides, such as lipopolysaccharide (LPS) and capsule (K antigen), contribute to the virulence of many bacterial pathogens by providing resistance to phagocytosis and protecting against complement-mediated killing, which is often measured as serum resistance. For E. coli, at least 80 distinct polysaccharide capsules have been identified, and they have been divided into 3 groups on the basis of their biochem-ical and physical properties and genetic organization [7] . In recent years, several studies have examined the role of polysaccharide capsules in the pathogenesis of UTI. Conclusions have been inconsistent. Russo et al. [8] could find no difference between the ability of the wild-type O4:K54:H5 blood isolate CP9 and that of an isogenic mutant deficient in the group 3 K54 capsule to colonize the mouse urinary tract. In contrast, Schneider et al. [9] reported that the K15 capsule of ExPEC strain 536 (O6:K15: H31) was important for virulence but not for serum resistance in a neonatal murine model of UTI. However, genetic complementation was not performed.
We have used 3 approaches to identify determinants that contribute to the urovirulence of ExPEC strain CFT073 (O6:K2: H1): signature-tagged mutagenesis (STM) [10] , comparisons of the genome of CFT073 with that of the laboratory K12 strain MG1655 [11, 12] , and analysis of genes transcribed specifically in vivo [13] . STM led to the identification of 3 independent attenuated mutants with insertions in genes involved in the biosynthesis of the group 2 K2 capsule [10] . A search of the CFT073 genome revealed that these genes are part of the capsule biogenesis locus within a pathogenicity island located at the pheV locus that includes other putative urovirulence determinants (aerobactin, 2 autotransporters, P fimbriae, and an RTX toxin) and is absent from the genome of E. coli MG1655 [12] . Microarray analysis indicated that genes for capsule biosynthesis were significantly up-regulated in bacteria recovered from the murine urinary tract or grown in human urine, compared with bacteria grown in laboratory medium [13] . In fact, the capsule locus was the only determinant identified in all 3 approaches (STM, genome analysis, and microarray analysis). These data imply a role for the K2 capsule in the pathogenesis of UTI. To test this hypothesis, we constructed an isogenic deletion mutation of the genes required for synthesis of the K2 capsule antigen, complemented the mutant, and tested the strains in a murine model of ascending UTI and in assays for resistance to serum and phagocytosis.
MATERIALS AND METHODS
Bacterial strains, plasmids, and urine samples. Characteristics of bacterial strains and plasmids used in this study are summarized in table 1. Bacteria were stored and cultured as described elsewhere [5] . Approval, informed consent, and procedures for obtaining and storing pooled human urine samples have been described elsewhere [13] .
Construction of a CFT073 capsule deletion mutant. To construct a mutant of the K2 capsule-specific locus (ksl[k2]) of strain CFT073, the 5 genes of region 2 (figure 1) were deleted and replaced with the chloramphenicol resistance gene by use of primer pair Donne-934 and Donne-978 (table 2) and the lambda red recombinase system [16] , with modifications as described elsewhere [20] . Chloramphenicol-resistant colonies were tested by polymerase chain reaction (PCR) analysis performed using primers Donne-936 and Donne-979 (table 2) , for replacement of region 2 with the chloramphenicol resistance marker. The chloramphenicol resistance marker was eliminated by expression of the FLP recombinase, as described elsewhere [17, 20] , and confirmed by PCR performed using primers Donne-936 and Donne-979 (table 2) . The resulting strain was named "UMD141." Identification of kps cosmid clones and subcloning of the kps K2 gene cluster. A genomic library of CFT073 chromosomal DNA [15] was systematically screened by PCR performed using primers Donne-930 and Donne-931, as described elsewhere [20] , to determine the presence of the kps gene cluster encoding all 3 regions involved in K2 capsule export and biosynthesis. A DNA fragment that contained ksl(k2)ABCDE, region 2 of the kps cluster, was amplified from cosmid clone 9-A1 by PCR performed using primers Donne-936 and Donne-979 and the Pfx DNA polymerase (Invitrogen), in accordance with the manufacturer's instructions. The PCR product was cloned into the TOPO blunt vector (Invitrogen) to create pXLW29 excised with EcoRI, and it was ligated to EcoRI-digested pWKS30 to create pXLW36.
Capsule staining and electron microscopy. Bacteria grown overnight in human urine under static conditions were stained with ferritin (1 g/mL; Sigma) and were examined using a JEOL 1200 EX transmission electron microscope, as described elsewhere [10] .
Experimental infections in mice. Urovirulence was assessed using a CBA mouse model of ascending UTI, as described elsewhere [10, 14] . In brief, CBA mice were transurethrally challenged with 10 8 cfu/mouse. After 48 h, urine was collected. The bladder and kidneys were removed, weighed, and homogenized, and dilutions were plated on selective media by use of a spiral plater. For cochallenge infections, mice were inoculated with a mixture of 5 ϫ 10 7 cfu of either the CFT073 rif wild-type strain and 5 ϫ 10 7 of the nalidixic acid-resistant mutant UMD141 (for a total of 10 8 cfu/inoculum) or of the mutant UMD141 strain containing the control plasmid pWKS130 and the complementing plasmid pXLW36. Because the lower limit of detection was 10 2 cfu, samples yielding no colonies were scored as having this value. A competitive index was calculated for each mutant, and statistical analysis was performed as described elsewhere [21] . Details are provided in the Appendix, which appears only in the electronic version of the Journal.
Polymorphonuclear leukocyte (PMNL) and serum preparations and opsonophagocytosis assay. PMNLs and serum were isolated, as described elsewhere [22] , from heparinized (50 U/mL) venous blood samples obtained from 1 healthy donor in all tests. In each experiment, serum samples were obtained from the same donor, under conditions that preserved complement activity, and the final concentration was 10% vol/vol. capsule is represented by the UTI89 sequence (GenBank accession no. CP000243); K5, by the Nissle 1917 isolate (GenBank accession no. AJ58688); and K15, by extraintestinal pathogenic E. coli strain 536 (GenBank accession no. CP000247). Enteroaggregative E. coli (EAEC) isolates Ec042 [19] and 101-1 (GenBank accession no. AAMK00000000) of unknown (UK) K serotype are also included. The partial sequence of the ExPEC strain CP9 K54 group 3 capsule cluster (GenBank accession no. AF007777) is shown for comparison. Colors correspond to genes that are similar (i.e., have Ͼ80% identity). Blue genes denote region 1; red genes, region 2 (deleted in mutant strain UMD141; see Materials and Methods); green genes, region 3; and gray genes, region 2 genes that were not similar (i.e., were Ͻ30% identical) to the CFT073 sequences. All 3 regions are absent from commensal E. coli strain HS; laboratory-adapted E. coli K12 strain W3110; enterohemorrhagic E. coli strains EDL933 and Sakai; enteropathogenic E. coli strains E22, E110019, and B171; and enterotoxigenic E. coli strains E23477A and B7A. The opsonophagocytosis assay was performed as described elsewhere [22] , with minor modifications. In brief, bacteria (grown in human urine to maximize capsule expression; 2.5 ϫ 10 4 cfu/well), normal human serum (10%), and Hanks' balanced salt solution with Ca 2ϩ and Mg 2ϩ supplemented with 0.1% bovine serum albumin were incubated in 96-well roundbottom microtiter plates. After 30 min at room temperature with shaking, PMNLs (2.5 ϫ 10 5 cells/well) were added, and the reaction was allowed to proceed for another 90 min. Samples (10 L) were obtained from each well immediately after the addition of PMNLs (time 0) and at the end of the reaction period. Counts of viable bacteria were obtained by plating serial dilutions on Luria-Bertoni agar with appropriate antibiotics. The percentage of surviving bacteria was calculated according to the following formula: (number of colony-forming units at 90 min/number of colony-forming units at 0 min) ϫ 100%. Control reactions consisted of wells with bacteria and serum without PMNLs or bacteria alone. In addition, all reactions were also performed with serum that had been heat inactivated at 56°C for 30 min.
RESULTS
Genomic organization of the capsular operon of ExPEC strain CFT073. The capsule locus of ExPEC strain CFT073 contains 13 open-reading frames [12] and is similar to that of other group 2 capsule loci [7] (figure 1). The overall guanine-cytosine content (41.45%) is significantly lower than that of the K12 E. coli genome (50.80%), suggesting a foreign origin. Genes within regions 1 and 3 of the kps K2 cluster, which encode enzymes required for the transport of capsule components, are highly homologous to those of other group 2 capsule loci. In contrast, the genes of region 2, designated "ksl(k2)ABCDE," are predicted to be responsible for the enzymatic synthesis of the polysaccharide and share no similarity with other E. coli sequences. Interestingly, the products of the ksl(k2)A and ksl(k2)C genes are similar to proteins involved in the synthesis of teichoic acid in grampositive organisms. The major features of the kps K2 genes and their putative functions are summarized in table 3, which appears only in the electronic edition of the Journal.
Construction of a kps K2 mutant impaired in capsule synthesis. Previous research [10] has demonstrated that CFT073 mutants with transposon insertions within kps genes had a reduced ability to compete with the wild-type strain to colonize the murine urinary tract. To provide conclusive evidence for the role of capsule in CFT073 virulence, we constructed a nonpolar mutant (strain UMD141) in which the entire biosynthetic region of the capsule locus (ksl[k2]ABCDE) was deleted. The growth rate of the mutant in human urine, as measured by determination of the bacterial count, was equivalent to that of the wild type (figure 2, which appears only in the electronic version of the Journal). In Luria broth, the mutant exhibited a slightly slower rate of increase in the optical density measured at 600 nm; this finding is consistent with the smaller size of the mutant, which results from the absence of capsule. Thin sections of wild-type CFT073 and mutant UMD141 strains grown in human urine were prepared and examined by electron microscopy for capsule production. As shown in figure 3 , no capsule could be detected in strain UMD141, whereas complementation of strain UMD141 with plasmid pXLW36 containing ksl(k2)ABCDE restored capsule expression. These results indicate that genes within region 2 are required for the production of K2 capsule.
Role of the K2 capsule in the pathogenesis of ascending UTI. To assess the role of K2 capsule in colonization of the murine urinary tract, wild-type CFT073 rif and ksl(k2)ABCDE mutant UMD141 strains were compared by transurethral inoculation. When administered alone, mutant strain UMD141 was able to colonize the urine, the bladder, and the kidneys at levels comparable to and not significantly different from those of wildtype strain CFT073 (data not shown). Thus, capsule does not appear to play a major role in colonization of the murine urinary tract, in experiments in which bacteria are inoculated separately.
For a more sensitive test of the role of capsule in colonization of the mouse urinary tract, we performed competitivecolonization experiments in which the wild-type strain CFT073 and the ksl(k2)ABCDE deletion mutant strain UMD141 were coinoculated in a 1:1 ratio. We found that the wild-type strain significantly outcompeted the mutant strain at 48 h in urine (P ϭ .003) and the kidneys (P ϭ .001). The difference in bladder colonization was not significant (P ϭ .078) (figure 4A). These results suggest that the ability to synthesize K2 capsule confers a competitive advantage for the wild-type strain. To confirm that this advantage is the result of capsular synthesis, we next performed competitive-colonization experiments comparing the mutant UMD141 with a complemented strain. Because the complemented strain has a plasmid, which might impair its fitness, we transformed UMD141 with the empty plasmid vector pWKS130. As shown in figure 4B , the complemented strain UMD141 (pXLW36) was recovered at significantly higher levels than was the mutant strain UMD141 (pWKS130) in the bladder (P ϭ .049) and urine (P ϭ 0.002). In the kidneys, the levels of colonization were not significantly different (P ϭ .475). These competitive-challenge experiments provide definitive evidence that synthesis of K2 capsule by CFT073 confers an advantage for survival within the murine urinary tract. Association between K2 capsule and protection from serum. To assess the role of the CFT073 K2 capsule in the development of resistance to killing by complement and phagocytes, we compared the ability of wild-type, capsule-deficient mutant, or complemented mutant strains to survive in the presence of human serum and PMNLs. As shown in figure 5 , there were no significant differences in the survival of the wild-type and the complemented mutant strains, under any of the conditions tested. However, significantly fewer colony-forming units of the ksl(k2)ABCDE mutant strain UMD141 (pWKS30) were recovered in the presence of human serum, compared with either the complemented strain UMD141 (pXLW36) (P ϭ .048) or the wild-type strain CFT073 (pWKS30) (P ϭ .002). No significant differences in survival among the strains were observed after incubation in the presence of heat-inactivated serum with or without PMNLs. However, even though all 3 strains were efficiently killed in the presence of serum plus PMNLs, the ksl(k2)ABCDE mutant strain was more susceptible to killing than was the wild-type strain (P ϭ .013). On the basis of these results, we conclude that the capsule of ExPEC strain CFT073 is required for serum resistance.
DISCUSSION
The ability to produce a polysaccharide capsule is a venerable trait among pathogenic bacteria. Indeed, early studies of capsule production in Streptococcus pneumoniae foretold the essential role of capsule in virulence and enabled the discovery that DNA carries genetic information [23, 24] . Of note, all of the leading species that cause bacteremia can produce capsules, suggesting that this property is indispensible for survival in blood [25] . Multiple lines of evidence, including the presence of group 2 capsule synthesis genes in ExPEC strains but not in E. coli K12 [12, 26, 27], higher expression in human urine and the murine urinary tract than in laboratory medium [13] , and identification of transposon insertion mutants outcompeted in the murine urinary tract [10] , suggested to us that capsule may also play an important role in UTI. To test this hypothesis, we generated a mutant of a highly urovirulent E. coli strain with precise deletion of capsule-specific synthesis genes, and we tested this strain, along with a complemented mutant, for the ability to cause ascending UTI in an animal model. Our results show conclusively that K2 capsule plays a significant role in this model. Further analysis indicated that the capsule-deficient mutant is more susceptible to the bactericidal effects of serum than is the wild-type strain. By fulfilling molecular Koch's postulates [28] , these results provide the first definitive evidence that capsule expression enhances the ability of E. coli to cause UTI. To our knowledge, this is the first study to demonstrate a role for capsule in any E. coli infection by use of precisely defined mutants and complemented strains.
The role of other group 2 capsules in E. coli infections has been studied for decades. K1 capsule production predominates among the subset of ExPEC strains that cause neonatal meningitis, and mutants deficient in K1 capsule production fail to induce high-grade bacteremia or penetrate the meninges in a neonatal rat model [29] . Mutants selected by virtue of serum resistance show reduced expression of K1 capsule, suggesting that K1 contributes to this phenotype [30] . In contrast, capsule mutants of O75:K5, O6:K5, and O18:K5 ExPEC strains selected using capsule-specific bacteriophages retain serum resistance, suggesting that the role of capsule may vary by capsule type or by other strain characteristics [31, 32] . However, because genetically defined mutations or verification by genetic complementation was not employed, these conclusions are tentative. The effect of serum and polymorphonuclear leukocytes (PMNLs) on the survival of wild-type and capsule-defective mutant strains of CFT073. Survival assays were performed with wild-type strain CFT073 that contained the control plasmid pWKS30 (white columns), ksl(k2)ABCDE mutant strain UMD141 (pWKS30) (black columns), and complemented mutant strain UMD141 (pXLW36) (hatched columns). The percentage of surviving bacteria was calculated according to the following formula: (number of colony-forming units at 90 min/number of colonyforming units at 0 min) ϫ 100%. Control bacteria were incubated in buffer without serum or PMNLs. Otherwise, bacteria were incubated in the presence of either 10% serum (serum), 10% heat-inactivated serum (HI-serum), PMNLs and 10% serum (serum ϩ PMNLs), or PMNLs and 10% heat-inactivated serum (HI-serum ϩ PMNLs). Error bars denote the SEM from 3 independent experiments.
Capsule production is common among ExPEC strains that cause UTI, but studies differ regarding whether capsule production is more common among urinary isolates than among control isolates of E. coli [33, 34] . In a previous study [31] , a capsuledeficient mutant of an O75:K5 ExPEC strain, selected for capsule-specific bacteriophage resistance after chemical mutagenesis, was outcompeted in the kidneys and bladder of C3H/ HeN mice by a capsule-expressing strain that had undergone several other undefined genetic manipulations. However, the mutant was not more susceptible to serum, statistical tests were not performed to determine whether the colonization differences were significant, the strains were not genetically defined, and complementation was not performed. In a more recent study, no difference in colonization of the murine urinary tract could be detected between an isogenic capsule-deficient mutant and the parent ExPEC strain expressing group 3 K54 capsule [8] , despite the fact that the mutant was more susceptible to serum [35] and less virulent than the parent strain after intravenous or intraperitoneal injection [36] . In contrast, capsule-deficient mutants of an O6:K15:H31 ExPEC strain caused less mortality than did the wild-type strain when injected through the skin into the bladder of neonatal mice, a model in which fatal infection is the norm [9] . These K15 mutants were not more susceptible to serum. Strain differences, including the type of capsule expressed, the type of O antigen, and numerous other factors, may be the source of disparate conclusions regarding the role of capsule in E. coli UTI. In addition, methodologic differences between the animal models may also play a role.
The strain of E. coli that we chose to study, CFT073 serotype O6:K2:H1, is representative of a widespread ExPEC lineage; related strains are commonly isolated from patients with bacteremia and women with UTI [37, 38] . Despite its prevalence, there has heretofore been scant information available on the K2 capsule and its role in virulence. The structure of the K2 capsule consists of repeating units of galactose, glycerol, and phosphate in a linear array reminiscent of teichoic acid, a component of the gram-positive cell wall [39, 40] . Close inspection of the sequence of region 2 of the capsule locus from ExPEC strain CFT073 partially illuminates the synthesis of this structure. The first gene in the region 2 operon, ksl(k2)A, is predicted to encode a glycerol-3-phosphate cytidyltransferase, and ksl(k2)C is predicted to encode a glycosyl transferase similar to enzymes involved in teichoic acid biogenesis. These enzymes presumably catalyze the addition of glycerol-3-phosphate and galactose to the growing polysaccharide chain at the cytoplasmic face of the cytoplasmic membrane [7] . The ksl(k2)B locus bears strong similarity to cpsC alleles of Actinobacillus pleuropneumoniae and capB alleles of Neisseria meningitidis serogroup Z, both of which play undefined roles in biosynthesis of specific capsule types. Finally, ksl(k2)D and ksl(k2)E do not resemble genes of known function, and, thus, a full understanding of how these loci contribute to capsule synthesis awaits further study.
To investigate the role of K2 capsule in ExPEC colonization of the urinary tract, we precisely deleted all 5 genes in region 2 of the capsule synthesis gene cluster. We targeted this region to minimize undesired adverse effects on the cell that might be caused by synthesis of capsule polysaccharide in the absence of a functional transport system. We confirmed that the mutant was unable to produce capsule and that capsule expression was restored by complementation with a plasmid bearing the deleted ksl(k2)ABCDE genes. The role of capsule was assessed by comparing the ksl(k2)ABCDE mutant with wild-type strain CFT073 in the murine model of ascending UTI. When inoculated together, the ksl(k2)ABCDE mutant was significantly outcompeted by the wild-type strain in the kidneys and urine and was recovered in lower numbers in the bladder. Complementation significantly improved survival of the mutant. It is likely that minor differences in recovery of bacteria from the various urinary compartments examined were the result of variation inherent in the model rather than different biological properties of capsule in different anatomical locations. Nevertheless, our data provide conclusive evidence that K2 capsule plays an important role in the pathogenesis of UTIs.
The primary function classically ascribed to bacterial capsules is inhibition of phagocytosis. Indeed, even though the wild-type, mutant, and complemented mutants were all efficiently killed in the presence of PMNLs and human serum, the mutant survived in significantly lower numbers than did the wild type under these conditions. That all strains survived well in the presence of PMNLs and heat-inactivated serum is consistent with the importance of complement-mediated opsonization for efficient phagocytosis and killing of this strain. Even so, the difference in survival between the wild type and the mutant in the presence of human serum alone was much more dramatic than that noted in the presence of PMNLs and serum. Under the former conditions, only the mutant was efficiently killed, a result confirmed by complementation. Because this effect was not seen with heatinactivated serum, these results strongly suggest that the K2 capsule protects the bacteria from the bactericidal effects of complement. Our findings are in agreement with those of Russo et al. [35] , who found that the K54 capsule of an ExPEC strain was required for resistance to killing via the alternative complement pathway. That there was a significant difference in killing in the presence of serum plus PMNLs, compared with serum alone, for the wild type, but not for the mutant, suggests that K2 capsule plays a more important role in serum resistance than in resistance to phagocytosis. Indeed, it appears that the survival difference between the wild type and the mutant in the presence of both serum and PMNLs is the result of an additive effect of killing by both complement and complement-mediated phagocytosis in the mutant versus killing by complement-mediated phagocytosis alone in the wild type.
Does the difference in serum resistance between the wild-type and capsule-deficient mutant strains account for the difference in ability to colonize the urinary tract? In the absence of disease states that induce proteinuria, human urine contains very low levels of complement proteins, but these levels increase with infection [41] . Thus, if serum resistance is relevant to urinary tract colonization, it is likely to play a role after the inflammatory response has begun. Additional studies of the time course of colonization, inflammation, and urinary complement levels will be required to answer this question and fully understand the role of capsule in urinary tract infections.
